Scarica l'app Stockscreener
1.97
2.07%
0.04
Precedente Chiudi:
$1.93
Aprire:
$2
Volume 24 ore:
11,044
Relative Volume:
0.05
Capitalizzazione di mercato:
$71.66M
Reddito:
-
Utile/perdita netta:
$-41.36M
Rapporto P/E:
-1.2012
EPS:
-1.64
Flusso di cassa netto:
$-42.09M
1 W Prestazione:
-5.29%
1M Prestazione:
+37.08%
6M Prestazione:
-8.37%
1 anno Prestazione:
-27.04%
Intervallo 1D:
$1.92
$2.0896
Intervallo di 1 settimana:
$1.90
$2.1986
Portata 52W:
$0.8981
$3.4154
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Nome
Armata Pharmaceuticals Inc
Settore
Industria
Telefono
310-655-2928
Indirizzo
4503 Glencoe Avenue, Marina del Rey, CA
Confronta ARMP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
1.98 | 72.39M | 0 | -41.36M | -42.09M | -1.64 |
|
ONC
Beone Medicines Ltd Adr
|
258.50 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.13 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.71 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-06-19 | Iniziato | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Borsa (ARMP) Ultime notizie
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - Seeking Alpha
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 44.0% - Defense World
10 Best Healthcare Stocks to Invest In (June 2025) - Securities.io
ARMP Soars 72% in a Month Following Infectious Disease Study Success - MSN
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Biotech Alert: Searches spiking for these stocks today - TipRanks
Armata Pharmaceuticals (ARMP) Experiences Massive Surge in Inter - GuruFocus
Armata Pharmaceuticals Q4 EPS Reduced by HC Wainwright - Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Price Target Raised to $9.00 at HC Wainwright - Defense World
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | ARMP Stock News - GuruFocus
Armata Pharmaceuticals (ARMP) Receives Boosted Price Target from - GuruFocus
HC Wainwright Adjusts Armata Pharmaceuticals Price Target to $9 From $7, Maintains Buy Rating - marketscreener.com
Armata Pharmaceuticals (ARMP) Price Target Boosted Following Cli - GuruFocus
ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Tria - GuruFocus
Armata reports data from Phase 1b/2a diSArm trial - TipRanks
Armata Pharmaceuticals Announces Positive Topline Data from the - GuruFocus
ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Trial | ARMP Stock News - GuruFocus
Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results - TipRanks
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PR Newswire
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates - MSN
Armata Pharmaceuticals Inc (ARMP) Q1 Earnings: EPS Loss of $0.18 - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update | ARMP Stock News - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - Financial Times
Armata Pharmaceuticals (ARMP) to Release Earnings on Tuesday - Defense World
Armata Pharmaceuticals secures additional DoD funding - Investing.com
Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 | ARMP Stock News - GuruFocus
Armata Pharmaceuticals secures additional DoD funding By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance
New Strong Sell Stocks for April 28th - The Globe and Mail
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World
Bacteriophage Therapy Market Future Business Opportunities - openPR
HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World
Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN
Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz
Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire
Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter
Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia
Armata Pharmaceuticals secures $10 million credit - Investing.com India
Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - Quantisnow
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 7.5% - MarketBeat
Armata Pharmaceuticals Inc Azioni (ARMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):